Cargando…
C781, a β-Arrestin Biased Antagonist at Protease-Activated Receptor-2 (PAR2), Displays in vivo Efficacy Against Protease-Induced Pain in Mice
Given the limited options and often harmful side effects of current analgesics and the suffering caused by the opioid crisis, new classes of pain therapeutics are needed. Protease-activated receptors (PARs), particularly PAR2, are implicated in a variety of pathologies, including pain. Since the dis...
Autores principales: | Kume, Moeno, Ahmad, Ayesha, Shiers, Stephanie, Burton, Michael D., DeFea, Kathryn A., Vagner, Josef, Dussor, Gregory, Boitano, Scott, Price, Theodore J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079573/ https://www.ncbi.nlm.nih.gov/pubmed/36417966 http://dx.doi.org/10.1016/j.jpain.2022.11.006 |
Ejemplares similares
-
PAR2 activation in the dura causes acute behavioral responses and priming to glyceryl trinitrate in a mouse migraine model
por: Mason, Bianca N., et al.
Publicado: (2023) -
Beta-arrestin inhibits CAMKKbeta-dependent AMPK activation downstream of protease-activated-receptor-2
por: Wang, Ping, et al.
Publicado: (2010) -
Development and Evaluation of Small Peptidomimetic Ligands to Protease-Activated Receptor-2 (PAR(2)) through the Use of Lipid Tethering
por: Boitano, Scott, et al.
Publicado: (2014) -
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
por: DeFea, K.A., et al.
Publicado: (2000) -
Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy
por: Ocasio-Rivera, Marinel, et al.
Publicado: (2020)